Reslizumab – All About Drugs
Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation - Respiratory Medicine
Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
Teva files MAA for asthma treatment reslizumab
FDA Will Review Teva's BLA for Asthma Drug Reslizumab
Brand name: Auvi-Q
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Upcoming Reslizumab PDUFA- Approval Odds, And What It Means For Teva (NYSE: TEVA) | Seeking Alpha
Reslizumab | New Drug Approvals
Teva announces FDA approval for asthma injection, Cinqair | Pharmafile
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Israeli Pharma gets FDA Approval for Asthma Antibody
New Severe Asthma Rx Gets Green Light | RxWiki
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
Reslizumab
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
cinqaero - Twitter Search / Twitter
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials - The Journal of Allergy and Clinical Immunology: In Practice
Subcutaneous Cinqair results add to Teva's troubles
BUY Reslizumab (CINQAIR) 10 mg/mL Teva Respiratory, LLC
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison - Journal of Allergy and Clinical Immunology
